New Healthcare Systems
Quick Facts on the Ecosystem
CVA has a unique expertise in the healthcare sector, with 100+ health-related projects carried out over the past five years in more than 50 countries across continents.
With an international multi-local team, the company partners with healthcare businesses across the world and intervenes throughout the product lifecycle, from early-stage innovation, clinical development, to go-to-market strategy and post-marketing phase.
Macro trends and business implications on the ecosystem:
Macro trends:
Ageing population with median age increasing with 20% by 2050.
Growing prevalence of chronic conditions as a 61% increase is anticipated among Americans younger than 50 by 2050.
Geopolitical polarization / regionalization bringing tensions on health supply security.
Uneven economic development, e.g. US drug being priced at 2.5 times higher than the average of other countries.
Budget security induced by political pressure on reducing cost efficiency to offset rising needs.
Digitalization and rise of AI leading to the adoption of digital tools and platforms in healthcare.
Climate change and biodiversity loss with new disease patterns and risks of zoonosis, as well as AMR.
Business implications:
Accelerated R&D: cutting-edge technologies and analytics to accelerate R&D programs are being leveraged to deliver cost savings, while an increasingly collaborative environment shares R&D risks to create disruptive innovation. Research is mainly driven by biotech companies and labs, with development by large pharmas, enabling the ability to foresee unmet market needs and expectations.
Era of Glocal production: new technologies are paving the way for multi purpose smaller scale manufacturing assets due to a growing emphasis on strategic autonomy. Production economics form a further dilemma as decisions need to be made between a scaled versus fragmented footprint with local presence, and a tailored treatment versus ability to scale. Simultaneously, environmental norms are increasingly pressuring costs.
Increased market access: broader value of medicines is being acknowledged, with new angles to value innovative drugs, and programmatic, environmental and societal value to be documented and communicated. Measures to contain costs are on the rise with tightening budgets for marketed drugs, pricing challenges for incremental innovation and rising expectations in terms of supply & CSR.
Direct marketing: patients are directly engaged in a tailored-way as specialized treatments and solutions are provided and patient- and customer-experience are enhanced with digital tools and platforms. Digital native companies or retail players can be better positioned to engage patients and customers, with digital platforms aiming for winner-takes-all moves.
Platform vision & service offering:
CVA’s vision is to have:
One health/global equity: broadening the perspective from just human health to an integrated global view, including planetary & animal health.
Holistic well-being: moving from purely medical care to a more holistic approach that encompasses mental, physical, and societal well-being.
Prevention & self-care: shifting the primary focus from merely treating or curing diseases to their prevention, and empowering individuals for self-care.
Patient centricity: transitioning from drug-centric approaches to patient-centric care with specific patient profile & needs: i.e., CAR T-cell therapy.
AI-powered data analytics: evolving from disparate databases to integrated, AI-driven data systems that can provide real-time insights & amp; predictive analytics.
CVA offers end-to-end support throughout the product lifecycle, from disease burden discovery to maximizing lifecycle value:
Discovery – Data-driven discovery of new R&D leads: Build 360 understanding of diseases by harnessing the power of data, and assess fit of solution with public health need and market expectations, and complementarity with company strategy, portfolio and capabilities.
Clinical development – Maximizing customer value from anticipation: Anticipate early regulatory and market access requirements in the clinical development plan, and regularly refresh the business case in terms of investment vs market potential and expected payback.
Go-to-market – Finding the right market positioning: Accelerate the go-to-market timeline, assess competing priorities for inclusion in NIP / reimbursement, analyse increasing interdependencies of price across countries.
Product maturity – Optimizing lifecycle value of your products: Reinvent market omnichannel engagement top grow market size, and best address new threats (e.g., IP challenges, competition of biosimilars, more stringent cost containment measures, risk of central tenderization).
Corporate portfolio stakes
Case Study
Evidence how innovative medicines can contribute to the decarbonization of healthcare systems
CVA has supported Big Pharma to Biotechs in multiple disease areas like vaccines, rare diseases and self-care, across a broad range of projects:
Franchise / brand strategy, such as R&D prioritization, brand plan elaboration, value proposition and objection handler, commercial strategy design, wargaming exercises to stress-test commercial strategy, customer plan elaboration, tender shaping & pricing strategy, CSR roadmap elaboration.
Market growth strategy, such as stakeholder engagement strategy and plan, country strategy to create momentum with health authorities, vaccination campaign risks mitigation & opportunities sizing, engagement materials…
Market entry / access strategy, such as vaccine positioning, product launch strategy, country launch sequence for a new vaccine, country-specific value proposition and objection handler, route-to-market strategies such as partnership strategies with key distributor…
Evidence generation strategy, such as respiratory disease surveillance system mapping, disease mapping through systematic literature review, modelling of budget impact, disease impact and cost effectiveness, expert consultations & scientific publications.
Platforms
-
Agri-Food Transition
Raising concern for food safety, quality, environmental impact.
-
Auto-Mobility
Working with car makers, national importers and leasing companies.
-
Energy & Circular Transition
Transforming the energy sector - power, oil, gas, industrial utilities.
-
Mining & Commodities
Shaping the future of earth minerals extraction, transformation and commercialization.
-
New Building Infrastructure & Construction
From affordable & sustainable construction to smart operational management.
-
New Healthcare Systems
Re-thinking healthcare systems and paving the way for innovative medicines.
-
New Service Models
Assisting financial institutions and services companies.